1,520 Alzheimers Headlines
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute
St. Joseph's Hospital and Medical Center
"2 NEW THERAPIES FOR ALZHEIMER'S"
Produced by MD Health Channel
Executive Editor.....Anne-Merete Robbs
CEO..............Stan Swartz

Dr. Reyes and his team are constantly working on new medicines and new solutions...You will receive news alerts...information on new trials as Dr Reyes announces them!
"2 NEW THERAPIES FOR ALZHEIMER'S"
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

St. Joseph's Hospital and Medical Center



DO YOU HAVE ALZHEIMERS?
 
"HELP DR. REYES... IN HIS BATTLE TO FIND A CURE...
.HE NEEDS YOUR HELP:
YOU CAN HELP WIN THE BATTLE FOR A CURE BY JOINING A TRIAL!!"....

Stan Swartz, CEO,
The MD Health Channel



"You'll receive all medication and study based procedures at
no charge

if you qualify for one of the many trials being conducted at Barrow Neurological Institute."
 

"Dr. Reyes Changed My Life"

- John Swartz
92 Years Old
Attorney at Law
"Dr.Reyes Changed My Life "
1:18
"At 92...I had lost my will to live"
5:48
Tips on Aging
2:29
"Dr. Reyes gave me customized health care"
2:09

Patricio Reyes M.D.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute

St. Joseph's Hospital and Medical Center
"PRESERVING BRAIN FUNCTIONS "
Runtime: 50:22
Runtime: 50:22
"2 NEW THERAPIES FOR ALZHEIMER'S"
Runtime: 10:27
Runtime: 10:27
ALZHEIMER'S AWARENESS PROGRAMS
Runtime: 5:00
Runtime: 5:00
BIOMEDICAL RESEARCH IN ALZHEIMER'S DISEASE
PDF Document 850 kb

Download Free

4 TALES OF NEUROSURGERY &
A PIANO CONCERT BY DR. SPETZLER...
Plus 2 books written by Survivors for Survivors!
Robert F. Spetzler M.D.
Director, Barrow Neurological Institute

J.N. Harber Chairman of Neurological Surgery

Professor Section of Neurosurgery
University of Arizona
TALES OF NEUROSURGERY:
A pregnant mother..a baby..faith of a husband.. .plus... Cardiac Standstill: cooling the patient to 15 degrees Centigrade!
Lou Grubb Anurism
The young Heros - kids who are confronted with significant medical problems!
2 Patients...confronted with enormous decisions before their surgery...wrote these books to help others!
A 1 MINUTE PIANO CONCERT BY DR. SPETZLER

Michele M. Grigaitis MS, NP
Alzheimer's Disease and Cognitive Disorders Clinic

Barrow Neurological Clinics
COPING WITH DEMENTIA
 
Free Windows Media Player Click

Links
Barrow Neurological Institute

Archives
October 2006  
November 2006  
December 2006  
January 2007  
February 2007  
March 2007  
May 2007  
June 2007  
November 2007  
December 2007  
April 2008  
July 2008  
August 2008  
September 2008  
October 2008  
November 2008  
December 2008  
January 2009  
February 2009  
March 2009  
April 2009  
May 2009  
February 2010  
March 2013  
May 2013  
November 2013  
January 2014  
February 2014  
March 2014  
April 2014  
May 2014  
June 2014  
July 2014  
June 2016  
July 2016  
August 2016  
September 2016  
October 2016  
November 2016  
December 2016  
January 2017  
February 2017  
March 2017  
April 2017  
May 2017  
June 2017  
July 2017  
August 2017  
September 2017  
October 2017  
November 2017  
December 2017  
January 2018  
February 2018  
March 2018  
April 2018  
May 2018  
June 2018  
July 2018  
August 2018  
September 2018  
October 2018  
November 2018  

This page is powered by Blogger. Isn't yours?

Thursday, April 27, 2017

 

This combo may trigger memory loss in Alzheimer’s















Low levels of a brain protein may combine with another long-suspected culprit to trigger the learning and memory losses in Alzheimer’s disease, a study shows.

The discovery should open up important new research areas, scientists say—and may one day lead to better therapies for the disease and other forms of cognitive decline.

“These findings represent something extraordinarily interesting about how cognition fails in human Alzheimer’s disease,” says Paul Worley, a neuroscientist at Johns Hopkins University School of Medicine and the senior scientist in the study.

Alzheimer’s is estimated to affect more than 5 million Americans. Clumps of proteins called amyloid plaques, long seen in the brains of Alzheimer’s patients, have often taken the blame for the mental decline associated with the disease.

But autopsies and imaging studies reveal that people can have high levels of amyloid in the brain without displaying Alzheimer’s symptoms, which calls into question a direct link between amyloid and dementia.

The new study, published in eLife, shows that when the NPTX2 gene produces less of its protein at the same time that amyloid is accumulating in the brain, circuit adaptations that are essential for neurons to work together are disrupted. That results in a failure of memory.

“The key point here is that it’s the combination of amyloid and low NPTX2 that leads to cognitive failure,” Worley says.

Worley’s lab group studies “immediate early genes,” so called because they’re activated almost instantly in brain cells when people and other animals have an experience that results in a new memory. NPTX2 is one of these immediate early genes; it makes a protein that neurons use to strengthen “circuits” in the brain.

“Those connections are essential for the brain to establish synchronized groups of ‘circuits’ in response to experiences,” Worley says. “Without them, neuronal activation cannot be effectively synchronized and the brain cannot process information.”

Worley says he was intrigued by studies indicating altered patterns of activity in brains of people with Alzheimer’s and wondered whether altered activity was linked to changes in immediate early gene function.

To get answers, researchers first turned to archived human brain tissue samples. They discovered that NPTX2 protein levels were reduced by as much as 90 percent in brain samples from Alzheimer’s patients. Samples with amyloid plaques from people who had never shown signs of AD had normal levels of NPTX2. This was an initial suggestion of a link between NPTX2 and cognition.

Alzheimer’s didn’t cause memory loss for these 90-year-olds

The scientists then examined mice bred without the rodent equivalent of the NPTX2 gene and discovered that a lack of NPTX2 alone wasn’t enough to affect cell function. But then they added a gene that increases amyloid generation to the mouse brains. In brain slices from mice with both amyloid and no NPTX2, fast-spiking interneurons could not control brain “rhythms” important for making new memories.

Examination of cerebrospinal fluid from 60 living Alzheimer’s patients and 72 people without the disease provided further evidence.

“Perhaps the most important aspect of the discovery is that NPTX2 reduction appears to be independent of the mechanism that generates amyloid plaques,” Worley says. “This means that NPTX2 represents a new mechanism.

One immediate application, he says, may be figuring out if NPTX2 levels can help identifying patients who can best be helped by new drugs. For instance, drugs that disrupt amyloid may be more effective in patients with relatively high NPTX2. Worley’s group is helping companies try to develop a commercial test that measures NPTX2 levels.

More work is needed, Worley adds, to understand why NPTX2 levels become low in Alzheimer’s and how to prevent or slow that process.


Story Source: The above story is based on materials provided by FUTURITY
Note: Materials may be edited for content and length